# PCD Versus RCD for the Treatment of Patients With Waldenstrom's Macroglobulinemia

> **NCT02971982** · PHASE1,PHASE2 · UNKNOWN · sponsor: **The First Affiliated Hospital of Soochow University** · enrollment: 40 (estimated)

## Conditions studied

- Treatment

## Interventions

- **DRUG:** rituximab /Dexamethasone/cyclophosphamide
- **DRUG:** Velcade/Dexamethasone/cyclophosphamide

## Key facts

- **NCT ID:** NCT02971982
- **Lead sponsor:** The First Affiliated Hospital of Soochow University
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2016-10
- **Primary completion:** 2018-10
- **Final completion:** 2018-12
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2016-11-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02971982

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02971982, "PCD Versus RCD for the Treatment of Patients With Waldenstrom's Macroglobulinemia". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02971982. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*